Publication:
Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).

cris.virtualsource.author-orcidf618d47b-2349-48a6-a9b4-74989a01812f
datacite.rightsopen.access
dc.contributor.authorBorradori, Luca
dc.contributor.authorVan Beek, N
dc.contributor.authorFeliciani, C
dc.contributor.authorTedbirt, B
dc.contributor.authorAntiga, E
dc.contributor.authorBergman, R
dc.contributor.authorBöckle, B C
dc.contributor.authorCaproni, M
dc.contributor.authorCaux, F
dc.contributor.authorChandran, N S
dc.contributor.authorCianchini, G
dc.contributor.authorDaneshpazhooh, M
dc.contributor.authorDe, D
dc.contributor.authorDidona, D
dc.contributor.authorDi Zenzo, G M
dc.contributor.authorDmochowski, M
dc.contributor.authorDrenovska, K
dc.contributor.authorEhrchen, J
dc.contributor.authorGoebeler, M
dc.contributor.authorGroves, R
dc.contributor.authorGünther, C
dc.contributor.authorHorvath, B
dc.contributor.authorHertl, M
dc.contributor.authorHofmann, S
dc.contributor.authorIoannides, D
dc.contributor.authorItzlinger-Monshi, B
dc.contributor.authorJedličková, J
dc.contributor.authorKowalewski, C
dc.contributor.authorKridin, K
dc.contributor.authorLim, Y L
dc.contributor.authorMarinovic, B
dc.contributor.authorMarzano, A
dc.contributor.authorMascaro, J-M
dc.contributor.authorMeijer, J M
dc.contributor.authorMurrell, D
dc.contributor.authorPatsatsi, K
dc.contributor.authorPincelli, C
dc.contributor.authorProst, C
dc.contributor.authorRappersberger, K
dc.contributor.authorSárdy, M
dc.contributor.authorSetterfield, J
dc.contributor.authorShahid, M
dc.contributor.authorSprecher, E
dc.contributor.authorTasanen, K
dc.contributor.authorUzun, S
dc.contributor.authorVassileva, S
dc.contributor.authorVestergaard, K
dc.contributor.authorVorobyev, A
dc.contributor.authorVujic, I
dc.contributor.authorWang, G
dc.contributor.authorWozniak, K
dc.contributor.authorYayli, S
dc.contributor.authorZambruno, G
dc.contributor.authorZillikens, D
dc.contributor.authorSchmidt, E
dc.contributor.authorJoly, P
dc.date.accessioned2024-10-11T16:46:04Z
dc.date.available2024-10-11T16:46:04Z
dc.date.issued2022-10
dc.description.abstractBACKGROUND Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. OBJECTIVES AND METHODOLOGY The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. RESULTS Treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. CONCLUSIONS The guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice.
dc.description.numberOfPages16
dc.description.sponsorshipUniversitätsklinik für Dermatologie
dc.identifier.doi10.48350/171017
dc.identifier.pmid35766904
dc.identifier.publisherDOI10.1111/jdv.18220
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/85919
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of the European Academy of Dermatology and Venereology : JEADV
dc.relation.issn1468-3083
dc.relation.organizationDCD5A442BAD9E17DE0405C82790C4DE2
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleUpdated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
oaire.citation.endPage1704
oaire.citation.issue10
oaire.citation.startPage1689
oaire.citation.volume36
oairecerif.author.affiliationUniversitätsklinik für Dermatologie
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2022-06-30 07:49:04
unibe.description.ispublishedpub
unibe.eprints.legacyId171017
unibe.refereedtrue
unibe.subtype.articlereview

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Acad_Dermatol_Venereol_-_2022_-_Borradori_-_Updated_S2_K_guidelines_for_the_management_of_bullous_pemphigoid_initiated_by.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format
File Type:
text
License:
https://creativecommons.org/licenses/by-nc-nd/4.0
Content:
published

Collections